Fortrea Holdings (FTRE) Non-Current Deferred Tax Liability (2022 - 2026)
Fortrea Holdings (FTRE) posted Non-Current Deferred Tax Liability of $92.3 million for Q1 2026, down 5.43% on a QoQ basis from $97.6 million in Q4 2025, and down 21.71% year-over-year from $117.9 million in Q1 2025.
Fortrea Holdings (FTRE) Non-Current Deferred Tax Liability (2022 - 2026) Analysis & Trends
Fortrea Holdings' Non-Current Deferred Tax Liability history runs 5 years deep, the most recent figure standing at $92.3 million for Q1 2026.
- Quarterly Non-Current Deferred Tax Liability fell 21.71% year-over-year to $92.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $92.3 million (down 21.71% YoY) and the FY2025 annual result came in at $97.6 million, down 19.8% from the prior year.
- Non-Current Deferred Tax Liability was $92.3 million for Q1 2026 at Fortrea Holdings, down from $97.6 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $184.5 million in Q4 2022 and bottomed at $92.3 million in Q1 2026.
- A 5-year average of $134.7 million and a median of $126.9 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability declined 26.11% — and 2025, when it retreated 15.76%.
- Fortrea Holdings' Non-Current Deferred Tax Liability stood at $184.5 million in 2022, then fell by 19.95% to $147.7 million in 2023, then decreased by 17.6% to $121.7 million in 2024, then decreased by 19.8% to $97.6 million in 2025, then retreated by 5.43% to $92.3 million in 2026.
- Business Quant data shows FTRE's Non-Current Deferred Tax Liability at $92.3 million in Q1 2026, $97.6 million in Q4 2025, and $106.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Fortrea Holdings | 1.83 Bn | 1.68 Bn | 123.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92.30 Mn |
| Mar 31, 2026 | 92.30 Mn |
| Dec 31, 2025 | 97.60 Mn |
| Dec 31, 2025 | 97.60 Mn |
| Sep 30, 2025 | 106.90 Mn |
| Sep 30, 2025 | 106.90 Mn |
| Jun 30, 2025 | 112.80 Mn |
| Jun 30, 2025 | 112.80 Mn |
| Mar 31, 2025 | 117.90 Mn |
| Mar 31, 2025 | 117.90 Mn |
| Dec 31, 2024 | 121.70 Mn |
| Dec 31, 2024 | 121.70 Mn |
| Sep 30, 2024 | 126.90 Mn |
| Sep 30, 2024 | 126.90 Mn |
| Jun 30, 2024 | 136.10 Mn |
| Jun 30, 2024 | 136.10 Mn |
| Mar 31, 2024 | 150.70 Mn |
| Mar 31, 2024 | 150.70 Mn |
| Dec 31, 2023 | 147.70 Mn |
| Dec 31, 2023 | 147.70 Mn |